Ronovo Surgical (Shanghai) Medical Technology Co., Ltd. ("Ronovo Surgical” or “Ronovo") completes a financing round of tens of millions of dollars. The round was led by LongRiver Investments, with participation from existing investors including Lilly AsiaVentures, Vivo Capital, Matrix Partners China, GGV Capital, who continue to show strong confidence and support in the company's development.

CEC Capital acted as the exclusive financial advisor for this financing round.

The proceeds from this funding will be used to accelerate the multi-disciplinary clinical trials of Ronovo Surgical's modular surgical robotic system, strengthen the research and development of platform-based products, enhance the clinical capabilities of the company, and enhance the company’s talent acquisition efforts.

Ronovo Surgical is developing a modular and versatile laparoscopic surgical robotic system tailored to the needs of Chinese laparoscopic surgeons. The system allows flexible selection of surgical instruments in terms of types, quantities, and arrangements, thereby extending and enhancing the laparoscopic surgical experience for physicians in various specialties, enabling a wide range of laparoscopic procedures to be performed on the robotic platform.